RxDoctor Payments Data

Lisa Vannoy

Nurse Practitioner · Davenport, IANPI 1447728712

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $2,059 and has fallen 98.8% since, to $24 in 2025. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,899in general payments, 2019–2025

Across 69 payments — averaging $42.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
  • Novartis$199
  • AstraZeneca$168
  • Merck$120
  • Johnson & Johnson$96
  • plus $165 from 5 others

What the payments were for

  • Travel & lodging$1,60055%
  • Food & beverage$1,28544%
  • Education$140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,899 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$17,649
Medicare patients
164
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan133$117,096
EliquisApixaban40$39,315
BrilintaTicagrelor43$34,512
FarxigaDapagliflozin Propanediol22$28,513
OzempicSemaglutide13$11,847
Potassium Chloride202$4,101
Ranolazine ErRanolazine36$2,580
Atorvastatin Calcium171$1,871
Furosemide228$1,468
Metoprolol Succinate119$1,227
Torsemide64$1,111
ClopidogrelClopidogrel Bisulfate76$1,077
Carvedilol131$836
Midodrine Hcl15$691
Losartan Potassium68$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$199$117,096133 claims
AstraZenecaBrilinta, Farxiga$168$63,02465 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →